SILVER SPRING, Md. — An FDA advisory committee voted 11-0 with one abstention to recommend approval carfilzomib (Kyprolis) for patients with treatment-refractory multiple myeloma.Members of the Oncologic Drugs Advisory Committee decided that the drug’s promised benefits — control of progressive disease in patients who have exhausted all other treatments — outweighed the considerable risks.”We need to put this in the context of patients who are really running out of options,” said one panel member prior to the vote.How Exciting! JUMP
